



July 30, 2018

Veracyte to Present at the Canaccord Genuity 38th Annual Growth Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 30, 2018-- [Veracyte, Inc.](#) (Nasdaq: VCYT) today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the Canaccord Genuity 38th Annual Growth Conference on Thursday, August 9, 2018 at 11:30 a.m. Eastern Time in Boston.

The live webcast of the presentation and a subsequent replay may be accessed by visiting Veracyte's website at <http://investor.veracyte.com>. The replay of the webcast will be available shortly after the conclusion of the presentation and archived on the company's website for 90 days following the presentation.

About Veracyte

Veracyte (Nasdaq: VCYT) is a leading genomic diagnostics company that is providing trustworthy and actionable answers that fundamentally improve patient care when current diagnostic tests are uncertain. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a \$2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180730005520/en/>

Source: Veracyte, Inc.

Veracyte, Inc.

Media:

Tracy Morris, 650-380-4413

tracy.morris@veracyte.com

or

Investors:

Keith Kennedy, 650-243-6357

Chief Financial Officer

keith@veracyte.com